Asymmetric dimethylarginine (ADMA) levels to investigate in patient with psoriasis

Aim: Psoriasis is associated with multiple comorbidities such as obesity, the metabolic syndrom and cardiovascular diseases. ADMA is a major inhibitor of nitric oxide sentase in humans. Recent reports have demonstrated that elevated hsCRP, is an inflammatory marker, and plasma ADMA levels are associated with endothelial dysfunction and increased atherogenesis. We aimed to determine by measuring the serum levels of ADMA and hsCRP in patients with psoriasis, whether endothelial dysfunction and psoriasis is an independent risk factor for cardiovascular disease.Methods: Thirty five psoriatic patientes and twenty six healty control grup were included into the study. Body mass index of all participants were measured and fasting blood samples were taken for the biochemical parameters. Serum levels of ADMA, HDL, LDL, trigliserid, total cholesterol, hsCRP and BMI were compared between patient and control subjects. The relationship between ADMA and hsCRP levels compared with PASI score.Results: There was no statistically significant difference between psoriatic and control groups for the demographic characteristics, and all laboratory parameterslevels. There was no significant relationship and correlation between PASI score and ADMA, BMI and laboratory parameters. Statiscally significant and modorate correlation was found between PASI score and hsCRP (r=0,73; p?0,01).Conclusion: Mild and modorate psoriasis is not independent risk factor for cardiovascular disease. Hovewer ıt is concluded that the levels of hsCRP can be used as an alternative marker to PASI for response to treatment and to determine the severity of the disaese.KEY WORDS: asymmetric dimethylarginine, high sensitive C reaktive protein, comorbidities, cardiovascular disease, psoriasis